Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 20/20 | 0.78 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.68 |
| ▸ | AURKA | O14965 | 1/20 | 0.63 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.63 |
| ▸ | KIT | P10721 | 1/20 | 0.63 |
| ▸ | BRAF | P15056 | 1/20 | 0.63 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.63 |
| ▸ | FLT1 | P17948 | 1/20 | 0.63 |
| ▸ | TEK | Q02763 | 1/20 | 0.63 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13856456 | 0.91 | KDR (0.81) | KDRFGFR1AURKAPDGFRBKIT | |
| SCHEMBL4282831 | 0.91 | KDR (0.82) | KDRFGFR1AURKAPDGFRBKIT | |
| SCHEMBL4286782 | 0.91 | KDR (0.77) | KDRFGFR1AURKAPDGFRBKIT | |
| SCHEMBL4769891 | 0.90 | KDR (0.76) | KDRFGFR1AURKAPDGFRBKIT | |
| SCHEMBL4286753 | 0.90 | KDR (0.77) | KDRFGFR1AURKAPDGFRBKIT | |
| SCHEMBL4292548 | 0.89 | KDR (0.76) | KDRFGFR1 | |
| SCHEMBL4282369 | 0.88 | KDR (0.86) | KDRFGFR1AURKAPDGFRBKIT | |
| SCHEMBL4290569 | 0.88 | KDR (0.75) | KDRFGFR1AURKAPDGFRBKIT | |
| SCHEMBL4292698 | 0.88 | KDR (1.00) | KDRAURKAPDGFRBKITBRAF | |
| SCHEMBL4278179 | 0.88 | KDR (0.77) | KDRFGFR1AURKAPDGFRBKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137580-A1 | Fused Heterocyclic Derivatives and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-28 | — | — | US | disclosed |
| US-20090137580-A1 | Fused Heterocyclic Derivatives and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-28 | — | — | US | disclosed |
| US-20090137580-A1 | Fused Heterocyclic Derivatives and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137580-A1 | Fused Heterocyclic Derivatives and Use Thereof | TIE1, KDR, FLT1 | KDR 2/4885FGFR1 14/4885AURKA 186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.